OM DENNA PODDSÄNDNING 🔗

Uppdateringsfrekvens:
every 21 days
Genomsnittlig ljudlängd:
9 minutes
Gästintervjuer
Engelsk
USA
213 avsnitt
sedan 2 augusti 2017
episodic

SENASTE AVSNITTET 🔗

Can routine cerebral embolic protection reduce stroke risk in TAVI? Rajesh Kharbanda and C. Michael Gibson discuss.

SÖK TIDIGARE AVSNITT

Sök efter tidigare avsnitt från Talking Points.

TIDIGARE AVSNITT

The FAME 3 Trial

William Fearon and C. Michael Gibson break down the final 5-year follow-up of the study comparing FFR-guided PCI vs CABG for patients with three-vessel CAD.
Saibal Kar and C. Michael Gibson look at the 2-year outcomes of transcatheter edge-to-edge repair for tricuspid regurgitation.
Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
Ansvarsfriskrivning: Podcasten och konstverket som är inbäddat på den här sidan är från TCTMD, som är dess ägares egendom och inte anslutet till eller godkänt av Listen Notes, Inc.